The reverse transcriptase inhibitors that are currently used to treat human immunodeficiency virus (HIV) could be also used in monogenic forms of SLE with mutated TREX1 or RNase H2 complex, which alter the metabolism of the nucleic acids that are generated during reverse transcription [153]. This evidence concerns the gene TREX1 and systemic lupus erythematosus.